Matches in Wikidata for { <http://www.wikidata.org/entity/Q88509856> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q88509856 description "artículu científicu espublizáu en mayu de 2018" @default.
- Q88509856 description "scientific article published on 30 May 2018" @default.
- Q88509856 description "wetenschappelijk artikel" @default.
- Q88509856 description "наукова стаття, опублікована в травні 2018" @default.
- Q88509856 name "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 name "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 type Item @default.
- Q88509856 label "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 label "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 prefLabel "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 prefLabel "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 P1433 Q88509856-D0024748-1787-48EA-B398-D83FFD04B841 @default.
- Q88509856 P1476 Q88509856-657EE2C2-47A1-46EF-A221-627E4DDC8936 @default.
- Q88509856 P2093 Q88509856-024485C3-A6C8-46D4-BB94-4F0FF2135B3C @default.
- Q88509856 P2093 Q88509856-0C949A00-27F7-46DB-8607-7F779BEDBEE4 @default.
- Q88509856 P2093 Q88509856-119BFEB3-6F1A-44FC-85D0-AA36292312D3 @default.
- Q88509856 P2093 Q88509856-4A65CC9E-0D04-4556-9009-836D92988441 @default.
- Q88509856 P2093 Q88509856-4C76388C-B076-46A1-9E1F-9FBF41C5DFA4 @default.
- Q88509856 P2093 Q88509856-61832E54-3532-4726-B5C4-880C582A05C6 @default.
- Q88509856 P2093 Q88509856-70D31DED-31DF-4837-AFD9-A0C4A315F6A5 @default.
- Q88509856 P2093 Q88509856-7880288D-1A9D-424E-83F1-DE21B3649A6D @default.
- Q88509856 P2093 Q88509856-93D8F8CF-0231-439E-8D6A-F1BFFED0F00A @default.
- Q88509856 P2093 Q88509856-9FAC24F9-8154-488E-9709-6C4E78F46297 @default.
- Q88509856 P2093 Q88509856-CDA1F8E9-F99E-4954-B420-12E034C0BD7A @default.
- Q88509856 P2093 Q88509856-E03D9A1A-EA40-4173-AAF0-D597763382BB @default.
- Q88509856 P304 Q88509856-B56D7094-F902-48E4-95B3-83E8E867A950 @default.
- Q88509856 P31 Q88509856-3510C772-0D65-4FF0-BC1E-68E952163207 @default.
- Q88509856 P356 Q88509856-806D608F-30CB-4036-AB68-F34EB7916F1B @default.
- Q88509856 P433 Q88509856-7C1344EA-DCD8-4169-9209-97FC15F60028 @default.
- Q88509856 P478 Q88509856-2D50298D-881E-49A7-A17D-DF2A687709C5 @default.
- Q88509856 P50 Q88509856-5AFD99BB-6898-4E1D-9BEE-EA0CCFA3EC41 @default.
- Q88509856 P577 Q88509856-54739987-8DE4-4BC3-B88C-0F0C68BC31E6 @default.
- Q88509856 P698 Q88509856-61537FC1-A8FD-4FBE-96A4-3C8F0742FF2A @default.
- Q88509856 P921 Q88509856-B908B15C-64C1-4898-AF75-E542BD8B7AC9 @default.
- Q88509856 P921 Q88509856-E52EC198-F609-4627-919F-527F3EF75B9A @default.
- Q88509856 P356 DOM.13338 @default.
- Q88509856 P698 29707866 @default.
- Q88509856 P1433 Q5270109 @default.
- Q88509856 P1476 "Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection" @default.
- Q88509856 P2093 "Da-Long Zhu" @default.
- Q88509856 P2093 "Gui-Yu Zhao" @default.
- Q88509856 P2093 "Shuang Ren" @default.
- Q88509856 P2093 "Tian-Xin Hu" @default.
- Q88509856 P2093 "Xiao-Wei Jin" @default.
- Q88509856 P2093 "Xiao-Xue Zhu" @default.
- Q88509856 P2093 "Xiao-Ying Li" @default.
- Q88509856 P2093 "Ya-Lin Li" @default.
- Q88509856 P2093 "Yan-Hua Ding" @default.
- Q88509856 P2093 "Yi Zhang" @default.
- Q88509856 P2093 "Yong-Guo Li" @default.
- Q88509856 P2093 "Yu Zhao" @default.
- Q88509856 P304 "2113-2120" @default.
- Q88509856 P31 Q13442814 @default.
- Q88509856 P356 "10.1111/DOM.13338" @default.
- Q88509856 P433 "9" @default.
- Q88509856 P478 "20" @default.
- Q88509856 P50 Q88509852 @default.
- Q88509856 P577 "2018-05-30T00:00:00Z" @default.
- Q88509856 P698 "29707866" @default.
- Q88509856 P921 Q3025883 @default.
- Q88509856 P921 Q864574 @default.